NCT00977795View on ClinicalTrials.gov

A Study of the Specificity and Sensitivity of 5-ALA Fluorescence in Malignant Brain Tumors

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2009

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
Brain Neoplasms
Interventions
DRUG

5-aminolevulinic acid

oral doses in phase 1 study of 10mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg and 50 mg/kg

Sponsors

Lead Sponsor

Endeavor Health
All Listed Sponsors
lead

Endeavor Health

OTHER

NCT00977795 - A Study of the Specificity and Sensitivity of 5-ALA Fluorescence in Malignant Brain Tumors | Biotech Hunter | Biotech Hunter